Graft Versus Host Disease Following HLA-Matched Sibling Donor Compared with Matched Related Donor for Hematopoietic Stem Cell Transplantation for the Treatment of Severe Combined Immunodeficiency Disease

• Published in: Journal of clinical immunology 2019-05, Vol.39 (4), p.414-420
• Main Authors: Al-Saud, Bandar, Al-Saleem, Alhanouf, Al Rasheed, Bashayer, Al-Ghonaium, Abdulaziz, Al-Ahmari, Ali, Al-Mousa, Hamoud, Al-Seraihy, Amal, Arnaout, Rand, Al-Jefri, Abdullah, Elshorbagi, Sahar, Elsayed, Nazeema, Al-Dhekri, Hasan, Ayas, Mouhab, Al-Muhsen, Saleh
• Format: Article
• Language: English
• Subjects: Biomedical and Life Sciences; Biomedicine; Graft-versus-host reaction; Hematopoietic stem cells; Histocompatibility antigen HLA; Immunology; Infectious Diseases; Internal Medicine; Limiting factors; Medical Microbiology; Original Article; Prophylaxis; Severe combined immunodeficiency; Statistical analysis; Stem cell transplantation; Stem cells; Transplants & implants
• ISSN: 0271-9142; 1573-2592
• DOI: 10.1007/s10875-019-00634-3

Background One of the limiting factors for successful hematopoietic stem cell transplantation (HSCT) is graft versus host disease (GVHD). The EBMT/ESID guidelines for HSCT in severe combined immunodeficiency (SCID) recommend no GVHD prophylaxis for a matched sibling donor (MSD). Objective To determine the risk of GVHD in MSD HSCT for SCID patients compared to matched related donor (MRD). Methods This retrospective cohort study compares MSD with MRD and the outcome of GVHD in all SCID patients who underwent HSCT between 1993 and 2013. All statistical analyses were done using IBM SPSS statistics software. Results One hundred forty-five SCID patients underwent 152 HSCTs while 82 (54%) received GVHD prophylaxis. GVHD occurred in 48 patients (31.5%); 20/48 (42%) had GVHD prophylaxis compared to 28/48 (58%) that did not, P  = 0.022. Acute GVHD occurred at a higher trend in MSD, 37/120 (30.8%), compared to MRD, 6/32 (18.8%), P  = 0.17. We also analyzed the outcome according to the period of HSCT. The first period was 1993 to 2003, 48 HSCTs, 43 MSD, 5 MRD; all patients had GVHD prophylaxis, and there was no difference in GVHD. The second period was 2004 to 2013: of 104 HSCTs, 77 had MSD and 27 had MRD; GVHD prophylaxis was used in 22.1% of MSD and 63% of MRD, P  = 0.000. GVHD was significantly higher in the MSD (40.2%) compared to MRD (18.5%) patients, P  = 0.041. Conclusion GVHD prophylaxis in MSD transplant should be considered in SCID patients.